alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<PAGE>   1
                                                                    Exhibit 10.8

Corixa Corporation
1124 Columbia Street
Suite 200
Seattle, WA 98104   USA
(206) 667-5711 Voice
(206) 667-5715 Fax



July 1, 1998

M. Charles de Taisne
Secretary General, External Research
Pasteur Merieux Connaught France
1541 Av. Marcel Merieux
69280 Marcy L'Etoile
FRANCE

RE:  EXTENDED OPTION TO LeIF

Dear Charles:

Thank you for your letter dated June 24, 1998 agreeing to further extend PMC's
option to LeIF. In accordance with our Letter Agreement dated December 17, 1997
(the "December Letter Agreement"), PMC's option to LeIF (the "Option"), pursuant
to the Option and License Agreement between Corixa and PMC, (the "Initial Option
Agreement"), would expire June 30, 1998. Based on our recent correspondence,
Corixa is willing to extend the Option, until the date (the "Option Termination
Date"), that is the earlier of (i) five (5) months following the date that
Corixa receives sufficient amounts of PMC's influenza vaccine to allow Corixa to
perform additional analysis of LeIF in accordance with the Research Plan,
attached as Exhibit A to the December Letter Agreement and (ii) December 31,
1998.

PMC will have the right to exercise the Option in one or more of the disease
fields available to PMC under the Initial Option Agreement by providing Corixa
written notice of exercise on or before the Option Termination Date. In the
event PMC exercises the Option, Corixa and PMC shall then enter into a license
agreement on the terms and conditions of the Initial Option Agreement.



<PAGE>   2
If the foregoing is acceptable, please sign as indicated below and return a copy
of this letter to my attention.

Best regards,

For CORIXA CORPORATION

/s/ Mark McDade

Mark McDade
Executive Vice President and
   Chief Operating Officer

Agreed and Accepted by:

PASTEUR MERIEUX CONNAUGHT FRANCE

/s/ Charles de Taisne
Charles de Taisne
Director Business Development
Pasteur Merieux Connaught France
**Exhibit
32(b)**
 
 **Certification
of Chief Financial Officer Pursuant to 18 U.S.C. § 1350**
 **(Section
906 of the Sarbanes-Oxley Act of 2002)**
 
 Pursuant
to 18 U.S.C. § 1350, the undersigned officer of Republic Bancorp Inc. (the
“Company”) hereby certifies, to such officer’s knowledge, that the Company’s
Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2005 (the
“Report”) fully complies with the requirements of Section 13(a) or 15(d), as
applicable, of the Securities Exchange Act of 1934 and that the information
contained in the Report fairly presents, in all material respects, the financial
condition and results of operations of the Company.
 
 
 Date:
      May 6, 2005
    /s/
      Thomas F. MenacherName:
      Thomas F. MenacherTitle:
      Executive Vice President, Treasurer and Chief Financial
      Officer
 
 The
foregoing certification (i) accompanies the filing and is being furnished solely
pursuant to 18 U.S.C. § 1350, (ii) will not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the
liability of that section, and (iii) will not be deemed to be incorporated by
reference into any filing under the Securities Act of 1933 or the Exchange Act,
except to the extent that the registrant specifically incorporates it by
reference.
 
 
 A signed
original of this written statement required by Section 906, or other document
authenticating, acknowledging, or otherwise adopting the signature that appears
in typed form within the electronic version of this written statement required
by Section 906, has been provided to Republic Bancorp Inc. and will be retained
by Republic Bancorp Inc. and furnished to the Securities and Exchange Commission
or its staff upon request.
### Geology and ground water of San Antonio Creek Valley, Santa Barbara County, California

By: K. S. Muir

                            https://doi.org/10.3133/wsp1664

#### Links

-                                                                                                                             Document:                                                                                                                                                                                                                                                  **Report**                                                                                                     (pdf)                                                                                                                                     
- Plates:                               - **Plate 1**                            (pdf)
  - **Plate 2**                            (pdf)
  - **Plate 3**                            (pdf)
  - **Plate 4**                            (pdf) 
- Download citation as:  RIS                         |                         Dublin                            Core

#### Abstract

Part or all of this report is presented in Portable Document Format                        (PDF). For best results viewing and printing PDF documents, it is recommended that you download                        the documents to your computer and open them with Adobe Reader. PDF documents opened from your                        browser may not display or print as intended. Download the latest version of Adobe Reader, free of charge. More information                        about viewing, downloading, and printing report files can be found at the common download problems FAQ.
§ 529.382 Chloramine-T. ( a ) *Specifications.* Chloramine-T trihydrate powder for solution.
( b ) *Sponsor.* See No. 086009 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.118 of this chapter.
( d ) *Conditions of use* — ( 1 ) *Freshwater-reared salmonids* — ( i ) *Amount.* 12 to 20 milligrams per liter (mg/L) water in a continuous flow water supply or as a static bath once per day for 60 minutes on consecutive or alternative days for three treatments.
( ii ) *Indications for use.* For the control of mortality in freshwater-reared salmonids due to bacterial gill disease associated with *Flavobacterium* spp.
( 2 ) *Walleye* — ( i ) *Amount.* 10 to 20 mg/L water in a continuous flow water supply or as a static bath once per day for 60 minutes on consecutive or alternative days for three treatments.
( ii ) *Indications for use.* For the control of mortality in walleye due to external columnaris disease associated with *Flavobacterium columnare.*
( 3 ) *Freshwater-reared warmwater finfish* — ( i ) *Amount.* 20 mg/L water in a continuous flow water supply or as a static bath once per day for 60 minutes on consecutive or alternative days for three treatments.
( ii ) *Indications for use.* For the control of mortality in freshwater-reared warmwater finfish due to external columnaris disease associated with *F. columnare.*
[79 FR 37621, July 2, 2014]
Exhibit 99.2

                           CERTIFICATION PURSUANT TO
                            18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Anaren  Microwave,  Inc. (the "Company")
on Form  10-K  for the  fiscal  year  ended  June  30,  2002 as  filed  with the
Securities and Exchange Commission on the date hereof (the "Report"),  I, Joseph
E.  Porcello,  Vice  President,  Finance and Treasurer of the Company,  certify,
pursuant to 18 U.S.C.  section 1350,  as adopted  pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

(2) The  information  contained in the Report fairly  presents,  in all material
respects, the financial condition and results of operations of the Company.

/s/ Joseph E. Porcello

Joseph E. Porcello
Vice President, Finance and Treasurer
August 6, 2002
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7617 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7617

         To prohibit no-knock warrants, and for other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 11, 2024

 Mr. McGarvey introduced the following bill; which was referred to the 
                       Committee on the Judiciary

_______________________________________________________________________

                                 A BILL

 
         To prohibit no-knock warrants, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Justice for Breonna Taylor Act''.

SEC. 2. PROHIBITION ON NO-KNOCK WARRANTS.

    (a) Federal Prohibition.--Notwithstanding any other provision of 
law, a Federal law enforcement officer (as defined in section 115 of 
title 18, United States Code) may not execute a warrant until after the 
officer provides notice of his or her authority and purpose.
    (b) State and Local Law Enforcement Agencies.--Beginning in the 
first fiscal year beginning after the date of enactment of this Act, 
and each fiscal year thereafter, a State or local law enforcement 
agency that receives funds from the Department of Justice during the 
fiscal year may not execute a warrant that does not require the law 
enforcement officer serving the warrant to provide notice of his or her 
authority and purpose before forcibly entering a premises.
                                 <all>
```
§ 582.1400 Lecithin. ( a ) *Product.* Lecithin.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
TEXAS COURT OF APPEALS, THIRD DISTRICT, AT AUSTIN

NO. 03-09-00500-CR

Charles Hamilton Jr., Appellant

v.

The State of Texas, Appellee

FROM THE DISTRICT COURT OF TRAVIS COUNTY, 299TH JUDICIAL DISTRICT

NO. D-1-DC-09-904060, HONORABLE CHARLES F. BAIRD, JUDGE PRESIDING

M E M O R A N D U M O P I N I O N

A jury found appellant Charles Hamilton Jr. guilty of burglary of a habitation with

intent to commit theft. See Tex. Penal Code Ann. § 30.02 (West 2003). The court assessed

punishment, enhanced by two previous felony convictions, at imprisonment for life.

Appellant’s court-appointed attorney has filed a motion to withdraw supported by a

brief concluding that the appeal is frivolous and without merit. The brief meets the requirements of

Anders v. California, 386 U.S. 738, 744 (1967), by presenting a professional evaluation of the

record demonstrating why there are no arguable grounds to be advanced. See also Penson v. Ohio,

488 U.S. 75 (1988); High v. State, 573 S.W.2d 807 (Tex. Crim. App. 1978); Currie v. State,

516 S.W.2d 684 (Tex. Crim. App. 1974); Jackson v. State, 485 S.W.2d 553 (Tex. Crim. App. 1972);

Gainous v. State, 436 S.W.2d 137 (Tex. Crim. App. 1969). Appellant received a copy of counsel’s
brief and was advised of his right to examine the appellate record and to file a pro se brief. See

Anders, 386 U.S. at 744. No pro se brief has been filed.

We have reviewed the record and find no reversible error. See Garner v. State,

300 S.W.3d 763, 766 (Tex. Crim. App. 2009); Bledsoe v. State, 178 S.W.3d 824, 826-27 (Tex. Crim.

App. 2005). We agree with counsel that the appeal is frivolous. Counsel’s motion to withdraw

is granted.

The judgment of conviction is affirmed.

___________________________________________

Jan P. Patterson, Justice

Before Justices Patterson, Puryear and Henson

Affirmed

Filed: July 15, 2010

Do Not Publish

2
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7705 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7705

  To amend the Internal Revenue Code of 1986 to expand the credit for 
        expenditures to provide access to disabled individuals.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 15, 2024

 Mr. Molinaro (for himself and Ms. Crockett) introduced the following 
      bill; which was referred to the Committee on Ways and Means

_______________________________________________________________________

                                 A BILL

 
  To amend the Internal Revenue Code of 1986 to expand the credit for 
        expenditures to provide access to disabled individuals.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Think DIFFERENTLY Small Business 
Accessibility Act''.

SEC. 2. EXPANDED CREDIT FOR EXPENDITURES TO PROVIDE ACCESS TO DISABLED 
              INDIVIDUALS.

    (a) In General.--Section 44(b)(1) of the Internal Revenue Code of 
1986 is amended--
            (1) in subparagraph (A), by striking ``$1,000,000'' and 
        inserting ``$3,500,000'', and
            (2) in subparagraph (B), by striking ``30 full-time 
        employees'' and inserting ``100 full-time employees''.
    (b) Effective Date.--The amendments made by this section shall 
apply to taxable years beginning after December 31, 2023.
                                 <all>
```
§ 54.6 Recordkeeping and record retention. ( a ) *Financial records of clinical investigators to be retained.* An applicant who has submitted a marketing application containing covered clinical studies shall keep on file certain information pertaining to the financial interests of clinical investigators who conducted studies on which the application relies and who are not full or part-time employees of the applicant, as follows: ( 1 ) Complete records showing any financial interest or arrangement as described in § 54.4(a)(3)(i) paid to such clinical investigators by the sponsor of the covered study.
( 2 ) Complete records showing significant payments of other sorts, as described in § 54.4(a)(3)(ii), made by the sponsor of the covered clinical study to the clinical investigator.
( 3 ) Complete records showing any financial interests held by clinical investigators as set forth in § 54.4(a)(3)(iii) and (a)(3)(iv).
( b ) *Requirements for maintenance of clinical investigators' financial records.* ( 1 ) For any application submitted for a covered product, an applicant shall retain records as described in paragraph (a) of this section for 2 years after the date of approval of the application.
( 2 ) The person maintaining these records shall, upon request from any properly authorized officer or employee of FDA, at reasonable times, permit such officer or employee to have access to and copy and verify these records.
<PAGE>

                                                                   Exhibit 10.22

                                              [LOGO OF ASTEA INTERNATIONAL INC.]

                                             December 1, 1999

PERSONAL AND CONFIDENTIAL
-------------------------

John G. Phillips
109 Forest Trail Drive
Lansdale, PA 19446

Dear Jack:

     As you and I have discussed, in consideration of your tenure with Astea
International Inc. (the "Company") and your agreement to continue your
employment with Company, the Company agrees that if at any time the Company
terminates your employment for any reason other than for "cause" (defined
below), the Company shall pay you the equivalent of six (6) months of your
salary and benefits, to be payable as if you were continuing as an employee.

     "Cause" is defined as conduct, as determined by the Board of Directors,
involving one or more of the following: (i) gross misconduct that is materially
injurious to the Company; or (ii) the commission of an act of embezzlement,
fraud or deliberate disregard for the rules or policies of the Company which
results in material economic loss, damage or injury to the Company; or (iii) the
unauthorized disclosure of any trade secret or confidential information of the
Company; or (iv) the commission of an act that induces any customer or
prospective customer of the Company to break a contract with the Company or to
decline to do business with the Company; or (v) your conviction of a felony
involving any financial impropriety or which would materially interfere with
your ability to perform your duties or would otherwise be injurious to the
Company; or (vi) your failure to perform in a material respect your employment
obligations without good reason.  In making such determination, the Board of
Directors shall act fairly and in utmost good faith.  If your employment is
terminated for cause, you will be notified of this at the time of termination.

If this is consistent with your understanding of our agreement, please indicate
this by signing below.

                                    Very truly yours,


                                    Bruce R. Rusch
                                    Chief Executive Officer

AGREED TO:
----------

___________________________
John G. Phillips
<PAGE>   1

                                                                     Exhibit 5.1

Data Dimensions, Inc.
One Bellevue Center
411 - 108th Avenue NE, Suite 2100 
Bellevue, Washington 98004


RE:    157,625 SHARES OF COMMON STOCK ($.001 PAR VALUE PER SHARE) OF DATA 
       DIMENSIONS, INC. (THE "COMPANY")

Ladies and Gentlemen:

         We have acted as counsel to you in connection with the preparation of a
Registration Statement on Form S-8 (the "Registration Statement") pursuant to
the Securities Act of 1933, as amended (the "Act"), which you are filing with
the Securities and Exchange Commission with respect to 157,625 shares of Common
Stock, $.001 par value per share (the "Shares"), which are to be issued pursuant
to the ST Labs, Inc. (formerly Software Testing Laboratories, Inc.) 1995 Stock
Option Plan and the ST Labs 1997 Stock Option Plan (collectively, the "Plans").
We have examined the Registration Statement and such other documents and records
of the Company, as we have deemed relevant and necessary for the purposes of
this opinion.

         Based upon and subject to the foregoing, we are of the opinion that the
Shares that will be issued pursuant to the Plans, upon the due execution by the
Company and the registration by its registrar of the Shares and the issuance
thereof by the Company in accordance with the terms of the Plans, and the
receipt of consideration therefor in accordance with the terms of the Plans,
will be validly issued, fully paid and nonassessable.

         We hereby consent to the filing of this opinion as an exhibit to the
Registration Statement. In giving such consent, we do not admit that we are in
the category of persons whose consent is required under Section 7 of the Act.

                                                  Very truly yours,



                                                  GARVEY, SCHUBERT & BARER
# C_2019060EN.01000101.xml

| 15.2.2019 | EN | Official Journal of the European Union | C 60/1 |
| --- | --- | --- | --- |

15.2.2019

EN

Official Journal of the European Union

C 60/1

---

COUNCIL RECOMMENDATION

of 12 February 2019

on the appointment of a member of the Executive Board of the European Central Bank

(2019/C 60/01)

THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty on the Functioning of the European Union, and in particular Articles 283(2) and 139(2) thereof,

Having regard to Protocol No 4 on the Statute of the European System of Central Banks and of the European Central Bank, and in particular Article 11.2 thereof,

HEREBY RECOMMENDS TO THE EUROPEAN COUNCIL THAT:

Mr Philip R. LANE be appointed as a member of the Executive Board of the European Central Bank for a term of office of eight years with effect from 1 June 2019.

Done at Brussels, 12 February 2019.

For the Council

The President

E.O. TEODOROVICI

---
### Regulatory Evaluation

Docket No. FAA- 

### 2012-0331 Directorate Identifier: 

### 2011-NM-119 -AD

If you make changes to the values in the table below, you must ensure the totals update accordingly. If

they do not, click (or Tab) into and then out of the changed cell

.

Estimated Costs:

Costs per Product (e.g., aircraft, engine,

propeller, appliance) Action

(e.g., Inspection,

replacement)

Do not include oncondition costs here Work-hours

(include

access, testing,

and close-up) Labor

cost

(@$85/h

our) Parts Cost Total Costs

(labor +

parts) Number of

U.S.

Registered

Products Total Cost

for U.S. Fleet



### Inspection 5.0 $ 425.00 $0 $ 425.00 

### 0 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00



### The known number of products in compliance:

Total Costs of compliance for U.S. fleet: $ 0



### Costs covered under warranty ( if known ) $

On-Condition Costs:

Action

(e.g., Inspection,

replacement) Work-hours

(include access,

testing, and closeup) Labor cost

(@$85/hour) Parts Cost Cost per Product



### Replacement 24.0 $2,040.00 $32,273 $34,313.20

$ 0.00 $ 0.00

$ 0.00 $ 0.00

$ 0.00 $ 0.00



### Special considerations for Economic Analysis (Use this field to explain anything in the Estimated Costs table

that was assumed or might not be obvious. This field can also be used to explain warranty costs) 

### :

### Executive Order 12866:

Could the AD be considered a “significant regulatory action”?

YES* NO

*Explanation:

DOT Regulatory Policies and Procedures:

Is the AD significant?

YES* NO

*Explanation:

Regulatory Flexibility Act:

Will the AD have a significant economic impact on a s ubstantial number of small entities? Explain for

either a Yes or No answer.

YES NO

Explanation:

Intrastate Aviation in Alaska:

This AD could affect intrastate aviation in Alaska. Is it appropriate to include specific requirements for

aircraft operated in Alaska where aviation might be the only mode of transportation?

YES* NO



### * Explanation 

### :
# C_2014071EN.01001201.xml

| 8.3.2014 | EN | Official Journal of the European Union | C 71/12 |
| -------- | -- | -------------------------------------- | ------- |

---

Request for a preliminary ruling from the Bundesgerichtshof (Germany) lodged on 3 January 2014 — Criminal proceedings against Thi Bich Ngoc Nguyen and Nadine Schönherr (Case C-2/14) (2014/C 71/20) Language of the case: German Referring court Bundesgerichtshof Parties to the main proceedings Thi Bich Ngoc Nguyen Nadine Schönherr Other party to the proceedings: Generalbundesanwalt beim Bundesgerichtshof Question referred Are medicinal products, as defined in Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use, ( 1 ) which contain ‘scheduled substances’ listed in Regulations (EC) No 273/2004 ( 2 ) and (EC) No 111/2005 ( 3 ) always excluded from the scope of those regulations in accordance with Article 2(a) of those regulations, or is that to be presumed only where the medicinal products are compounded in such a way that the scheduled substances cannot for the purposes of those regulations be easily used or extracted by readily applicable or economically viable means? ( 1 )  OJ 2001 L 311, p. 67. ( 2 )  Regulation (EC) No 273/2004 of the European Parliament and of the Council of 11 February 2004 on drug precursors (OJ 2004 L 47, p. 1). ( 3 )  Council Regulation (EC) No 111/2005 of 22 December 2004 laying down rules for the monitoring of trade between the Community and third countries in drug precursors (OJ 2005 L 22, p. 1).

---